TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31194946

Group type: EXPERIMENTAL
Intervention: Low-dose extracorporeal shockwave therapy (ESWT) for 4 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (sham shockwave therapy)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Low-dose extracorporeal shockwave therapy (ESWT)
Number of subjects: 63
Study: 28167188

Group type: EXPERIMENTAL
Intervention: PNF stretching
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study: 25295834

Group type: EXPERIMENTAL
Intervention: Pharmacist led patient self-testing (PST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care (management in a hospital based anti-coagulation clinic)
Number of subjects: 0
Study: 23421968

Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol combination (FSC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 15
Study: 21744732

Group type: EXPERIMENTAL
Intervention: propofol+remifentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: propofol+alfentanil
Number of subjects: 30
Study: 19347118

Group type: COMPARATOR
Intervention: Intravitreal antibiotic injection, associated with topical and oral antibiotics (Group 1, n=24)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy and silicone oil injection with intravitreal antibiotic injection (Group 2, n=11)
Number of subjects: 35
Study: 16920897

Group type: EXPERIMENTAL
Intervention: Dapoxetine (C(max) in young men: 338 ng/mL; elderly men: 310 ng/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapoxetine (AUC in young men: 2040 ng x h/mL; elderly men: 2280 ng x h/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dapoxetine with food (C(max) in fed state: 398 ng/mL; fasted state: 443 ng/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dapoxetine with food (AUC)
Number of subjects: 0
Study: 15228505

Group type: EXPERIMENTAL
Intervention: Flipperport
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Jordy
Number of subjects: 20

Group type: COMPARATOR
Intervention: HMDs (Jordy, Flipperport, Maxport, NuVision)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional optical aids (LVAs)
Number of subjects: 20
Study: 11354238

Group type: EXPERIMENTAL
Intervention: Zotepine (50-450 mg, mean 207 +/- 125 mg/day)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 108
Study: 9244025

Group type: EXPERIMENTAL
Intervention: Acupuncture at the PC6 point
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 8489310

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MM) in maintenance immunosuppression regimen
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MM) for reversing refractory renal allograft rejection
Number of subjects: 47
Study: 3514949

Group type: EXPERIMENTAL
Intervention: Endometrial thickness and texture assessment during IVF induction
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Endometrial thickness measurement
Number of subjects: 320
Study: 29106814

Group type: EXPERIMENTAL
Intervention: Multi-ingredient nutritional supplement (SUPP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbohydrate-based control (CON)
Number of subjects: 0
Study: 27088998

Group type: EXPERIMENTAL
Intervention: Atomized lidocaine (4% lidocaine, 2 mg/kg) administered using a mucosal atomization device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonatomized lidocaine (4% lidocaine, 2 mg/kg) administered using a traditional spray tube
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atomized lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonatomized lidocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both atomized and nonatomized lidocaine
Number of subjects: 20
Study: 25465686

Group type: EXPERIMENTAL
Intervention: Hydrogel sealant (Resure)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Nylon suture
Number of subjects: 500
Study: 23070488

Group type: EXPERIMENTAL
Intervention: 4.5 hours in bed (sleep restriction)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 8.5 hours in bed (normal sleep)
Number of subjects: 7
Study: 16056048

Group type: EXPERIMENTAL
Intervention: Interax ISA mobile platform total knee arthroplasties
Number of subjects: 35
Study: 12002728

Group type: EXPERIMENTAL
Intervention: Anti-allergic mattress encasings
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 9467442

Group type: EXPERIMENTAL
Intervention: ProTek (Vifilcon A) therapeutic soft contact lens
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (standard postoperative care)
Number of subjects: 47
Study: 8586079

Group type: EXPERIMENTAL
Intervention: Finger probing allowed for normal subjects
Number of subjects: 26

Group type: COMPARATOR
Intervention: Finger probing allowed for CTS subjects
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Finger probing not allowed for normal subjects
Number of subjects: 26

Group type: COMPARATOR
Intervention: Finger probing not allowed for CTS subjects
Number of subjects: 26
Study: 2186274

Group type: EXPERIMENTAL
Intervention: Intervention group (display of charges for tests)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intervention group (scheduled visits)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intervention group (unscheduled visits)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intervention group (post-intervention)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study: 707334

Group type: EXPERIMENTAL
Intervention: Essential amino acids and alpha-keto acid analogues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Keto acid analogue therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-hydroxy acid analogues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 0
Study: 31984652

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 28

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All assessed survivors
Number of subjects: 28
Study: 30841823

Group type: EXPERIMENTAL
Intervention: BCAA (6 g/day) with vitamin B6 (40 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 28169153

Group type: EXPERIMENTAL
Intervention: WT alone (FSG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WT combined to jump and sprint exercises (COM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study: 26152131

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg infusions administered every 8 or 12 hours (q8h or q12h)
Number of subjects: 67
Study: 24088189

Group type: EXPERIMENTAL
Intervention: Boswellia Serrata (BS) capsules for 6 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 38
Study: 21119150

Group type: EXPERIMENTAL
Intervention: Treatment adherence therapy (TAT)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 109
Study: 18805249

Group type: EXPERIMENTAL
Intervention: 10-week CBSM group intervention (n=21)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 1-day CBSM workshop (n=18)
Number of subjects: 39
Study: 17079573

Group type: EXPERIMENTAL
Intervention: Combined therapy of erythropoietin, iron, folate, and vitamin B12
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12941710

Group type: EXPERIMENTAL
Intervention: Combination therapy (10-15 mg sibutramine daily, low-calorie diets using meal replacement products for 1 week every 2 months, and daily use of meal replacement product and snack bars)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 10986106

Group type: EXPERIMENTAL
Intervention: Caffeinated drink consumed after 12 h caffeine deprivation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeine-deprived group who no longer received caffeine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Non-deprived state groups
Number of subjects: 36
Study: 8742095

Group type: EXPERIMENTAL
Intervention: Bicalutamide in combination with LHRH analogs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flutamide in combination with LHRH analogs
Number of subjects: 0
Study: 1418054

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg/d for 3 days, then 2 x 10 mg/d for 39 days)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 3882680

Group type: EXPERIMENTAL
Intervention: Fluoxetine once a day (in the morning)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine twice a day (in the morning and at noon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine (both regimens)
Number of subjects: 0
Study: 31512923

Group type: EXPERIMENTAL
Intervention: Exercise video games (EVGs)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard exercise (e.g., treadmill walking, stationary cycling)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Treatment (EVGs or standard exercise)
Number of subjects: 189
Study: 30463809

Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation of the right inferior frontal cortex (rIFC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 80
Study: 27490922

Group type: EXPERIMENTAL
Intervention: ω-3 Fatty Acid Ethyl Esters (4 g/d)
Number of subjects: 0
Study: 25131734

Group type: EXPERIMENTAL
Intervention: Sabin IPV (20:32:64 DU/dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adjuvanted Sabin IPV (10:16:32 DU/dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional Salk IPV (40:8:32 DU/dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All vaccination groups
Number of subjects: 60
Study: 22607857

Group type: COMPARATOR
Intervention: Canadian patients
Number of subjects: 2086
Study: 19074536

Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/day)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Haloperidol (8-30 mg/day)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160 mg/day) during extension phase
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Haloperidol (4-30 mg/day) during extension phase
Number of subjects: 438
Study: 18400631

Group type: COMPARATOR
Intervention: Regular cigarette smoking
Number of subjects: 38

Group type: COMPARATOR
Intervention: Mentholated cigarette smoking
Number of subjects: 38
Study: 16036285

Group type: EXPERIMENTAL
Intervention: Spontaneous smoking reduction among past reducers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender and number of heart disease diagnoses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age and history of chronic obstructive pulmonary disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotinine and nicotine levels per cigarette per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spontaneous reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Past history of heart disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compensation among past spontaneous reducers
Number of subjects: 0
Study: 12448875

Group type: EXPERIMENTAL
Intervention: Religious psychotherapy (RPT)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 4
Study: 10510053

Group type: EXPERIMENTAL
Intervention: Abciximab (a platelet glycoprotein IIb/IIIa receptor antagonist)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: TnT-positive patients (TnT levels >0.1 microg/L)
Number of subjects: 853

Group type: COMPARATOR
Intervention: TnT-negative patients (TnT levels ≤0.1 microg/L)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: TnT-positive patients
Number of subjects: 853
Study: 7571666

Group type: EXPERIMENTAL
Intervention: Jejunal interposition with pouch (JIP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Roux-en-Y pouch reconstruction (RYP)
Number of subjects: 120
Study: 1827104

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg every 12 h
Number of subjects: 243

Group type: COMPARATOR
Intervention: Penicillin VK 250 mg every 6 h
Number of subjects: 243
Study: 7300705

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 24
Study: 30343264

Group type: EXPERIMENTAL
Intervention: Web-based education program
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard clinic-based GDM education (Control)
Number of subjects: 110
Study: 28219190

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided group (PCT group)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Regular antibiotic group (RAT group)
Number of subjects: 156
Study: 25597563

Group type: EXPERIMENTAL
Intervention: Lower systolic blood pressure (SBP)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Lower diastolic blood pressure (DBP)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Lower mean arterial pressure (MAP)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Higher functional ability (control group)
Number of subjects: 430
Study: 23744506

Group type: EXPERIMENTAL
Intervention: Recombivax 2.5 µg
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Challenge dose of vaccine
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Booster dose
Number of subjects: 560
Study: 20400649

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with lidocaine and its metabolite (MEGX)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with bupivacaine enantiomers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with lidocaine and its metabolite (MEGX) and bupivacaine enantiomers
Number of subjects: 10
Study: 19263132

Group type: EXPERIMENTAL
Intervention: Skin adhesives
Number of subjects: 404

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 404
Study: 17166593

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the left DLPFC
Number of subjects: 26

Group type: COMPARATOR
Intervention: Anodal occipital tDCS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 26
Study: 15709453

Group type: EXPERIMENTAL
Intervention: TAA AQ (triamcinolone acetonide), 220 microg, once daily for 3 weeks
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: FP (fluticasone propionate), 200 microg, once daily for 3 weeks
Number of subjects: 295
Study: 11182836

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Sustained-release dexfenfluramine
Number of subjects: 914

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 914
Study: 9702146

Group type: EXPERIMENTAL
Intervention: Community policies to reduce youth access to tobacco (intervention communities)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 14
Study: 8287743

Group type: EXPERIMENTAL
Intervention: Pouchitis patients (Group 2)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Normal pouch patients (Group 1)
Number of subjects: 78
Study: 2978997

Group type: EXPERIMENTAL
Intervention: Isradipine 7.5 mg three times daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31327184

Group type: EXPERIMENTAL
Intervention: 10-day concomitant therapy (CT)
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (ST)
Number of subjects: 1141

Group type: COMPARATOR
Intervention: 7-day clarithromycin-containing triple therapy (TT)
Number of subjects: 1141
Study: 30672218

Group type: EXPERIMENTAL
Intervention: Combined therapy group (acupuncture + five-element music therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Electroacupuncture (EA) group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Five-element music therapy group
Number of subjects: 120
Study: 27448223

Group type: EXPERIMENTAL
Intervention: UPD plus adjunct aPDT
Number of subjects: 20

Group type: COMPARATOR
Intervention: UPD only
Number of subjects: 20
Study: 24835009

Group type: EXPERIMENTAL
Intervention: Zinc treatment at home (10-day course)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS) at home
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Zinc treatment at home
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: ORS use
Number of subjects: 440
Study: 22676245

Group type: EXPERIMENTAL
Intervention: TAS-108 40 mg/day
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: TAS-108 80 mg/day
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: TAS-108 120 mg/day
Number of subjects: 97
Study: 20100026

Group type: EXPERIMENTAL
Intervention: 340 mg oral magnesium (170 mg twice a day) for 6.5 months
Number of subjects: 55
Study: 18714904

Group type: EXPERIMENTAL
Intervention: Universal screening for intimate partner violence (IPV) using a standard set of questions during home visits.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: In-depth assessment of the family for mothers' exposure to IPV as part of the Healthy Babies Healthy Children program.
Number of subjects: 6
Study: 15743278

Group type: EXPERIMENTAL
Intervention: Higher homocysteine levels
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Increase in homocysteine levels from the 25th to the 75th percentile
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Subjects in the highest quartile of homocysteine levels
Number of subjects: 1140
Study: 11487039

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWH) in fixed doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LMWH in high prophylactic doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: LMWH and UFH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin in high prophylactic doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentasaccharide
Number of subjects: 0
Study: 9431632

Group type: EXPERIMENTAL
Intervention: Physician intervention (notification of risk and recommendations for care)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group (no physician intervention)
Number of subjects: 268
Study: 8500297

Group type: EXPERIMENTAL
Intervention: Short-term oral digoxin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 34
Study: 3805752

Group type: EXPERIMENTAL
Intervention: Leukotriene D4 (LTD4) at doses of 3.1‐200 pmol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: H1 and H2 antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local nerve block
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leukotriene D4 (LTD4) at doses of 0.2‐200 pmol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Occlusion of vasculature to the test arm before injection of LTD4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent injections of LTD4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leukotriene D4 (LTD4) injections
Number of subjects: 0
Study: 2524387

Group type: EXPERIMENTAL
Intervention: Intravenous administration of ipratropium bromide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral administration of ipratropium bromide (20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhalation of ipratropium bromide
Number of subjects: 10
Study: 31619483

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 30
Study: 27861703

Group type: EXPERIMENTAL
Intervention: Birthweight discordance >75th percentile
Number of subjects: 1688

Group type: EXPERIMENTAL
Intervention: Birthweight discordance >90th percentile
Number of subjects: 1688

Group type: EXPERIMENTAL
Intervention: Birthweight discordance
Number of subjects: 1688
Study: 25667159

Group type: EXPERIMENTAL
Intervention: 2-thumb-encircling hands technique
Number of subjects: 27

Group type: COMPARATOR
Intervention: 2-finger technique
Number of subjects: 27
Study: 23525929

Group type: EXPERIMENTAL
Intervention: Automated weaning
Number of subjects: 92

Group type: COMPARATOR
Intervention: Protocolized weaning
Number of subjects: 92
Study: 21646062

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) for ISR
Number of subjects: 872

Group type: COMPARATOR
Intervention: De novo lesions
Number of subjects: 872
Study: 19181826

Group type: EXPERIMENTAL
Intervention: TIP (paclitaxel 175 mg/m(2) + cisplatin 75 mg/m(2) + ifosfamide 5 g/m(2))
Number of subjects: 154

Group type: COMPARATOR
Intervention: TP (paclitaxel 175 mg/m(2) + cisplatin 75 mg/m(2))
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: TIP
Number of subjects: 154

Group type: COMPARATOR
Intervention: TP
Number of subjects: 154
Study: 16434666

Group type: EXPERIMENTAL
Intervention: Creatine 8 g/day for 16 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 15117853

Group type: EXPERIMENTAL
Intervention: ST2 levels measured in serum
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: ST2 quartiles analysis
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: ST2 levels at 12 hours post-infarction
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis controlling for clinical factors
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: In-hospital ST2 levels
Number of subjects: 810
Study: 11697020

Group type: EXPERIMENTAL
Intervention: Active treatment (n = 50)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (n = 51)
Number of subjects: 101
Study: 9231950

Group type: EXPERIMENTAL
Intervention: 120-minute nap
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 15-minute nap
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 120-minute nap (sleep-deprived subjects)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 120-minute nap (narcoleptic patients)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 15-minute nap (narcoleptic patients)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 15-minute nap (sleep-deprived subjects)
Number of subjects: 33